Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer
Chia‐Chi Hsu(National Yang Ming Chiao Tung University), James Chih‐Hsin Yang(National Taiwan University)
Cited by 83
Related Papers
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
|JAMA Oncology|2017|632
Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
|PLoS ONE|2015|48
Energy metabolism determines the sensitivity of human hepatocellular carcinoma cells to mitochondrial inhibitors and biguanide drugs
|Oncology Reports|2015|36
CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer
|Anticancer Research|2021|28
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC
|Journal of Biomedical Science|2025|1